Thu, May 02, 2024
Bharat Biotech highlighted a few milestones achieved by COVAXIN, an indigenous COVID-19 vaccine developed by it in collaboration with the Indian Council of Medical Research (ICMR).
More >
Mon, Aug 15, 2022
BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries, a press release from the vaccine maker said.
Wed, Aug 10, 2022
India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.
Wed, Jun 09, 2021
On Tuesday, the Union Ministry has announced price caps for the administration of COVID-19 vaccines in private hospitals.
Mon, Jun 07, 2021
With the COVID-19 vaccination drive going on across the country, there is a query for which several people are looking for answers. Which COVID-19 vaccine is more effective? Covishield or Covaxin?
Tue, Jun 01, 2021
NITI Aayog Member (Health) Dr. Vinod Kumar Paul has today again repeated that there is absolutely no change in the schedule of Covishield and Covaxin doses. There will be two doses only for both.
Thu, May 13, 2021
India is currently in the third phase of the nationwide vaccination drive where people above the age of 18 years are getting vaccinated. However, the nation is facing a big shortage in the number of vaccines delivered as demand has surged in the face of rising number of Covid-19 cases.
Sun, Apr 25, 2021
Covid 19 vaccines price: Bharat Biotech has announced the price of Covid 19 vaccine for state and private hospitals. The decision comes on the directive of the India government. Earlier this week, Serum Institute of India (SII) had also revealed prices of its vaccine.
Wed, Mar 03, 2021
Indian company Biotech has released the data for the third phase trial of its CORONA vaccine (COVAXIN). It has claimed that the vaccine is 81% effective.
Bharat Biotech on Wednesday announced the phase 3 results of its coronavirus vaccine ‘Covaxin’ claiming the shots have demonstrated an interim clinical efficacy of nearly 81%.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
